Skip to main content
Equibles
PBYI logo

PBYI · Puma Biotechnology, Inc. · Metrics

Track PBYI — free

Use PBYI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PBYI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.61 -0.31 (-2.84%) Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$563.69M
Shares
51.62M
Volume · Oct 28 170.68K Avg daily vol (3M) 328.93K

PBYI metrics

101 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$10.92
Market cap
$563.69M

Price action

20 metrics
Price change (1W)
+1.5%
Price change (30D)
+11.2%
Price change (3M)
+37.0%
Price change (6M)
+44.8%
Price change (YTD)
+83.5%
Price change (1Y)
+107.2%
Trailing year
Price change (5Y)
+108.8%
52-week high
$11.26
52-week low
$4.73
Change from 52-week high
-3.0%
Change from 52-week low
+130.9%
Annualized volatility
59.2%
Annualized volatility (3M)
43.0%
Beta
0.6
RSI (14D)
61.6
Price vs SMA 50
+12.1%
Price vs SMA 200
+39.1%
Avg volume (3M)
328,932
Relative volume
0.9
Average dollar volume
$3.11M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
51.62M

Valuation

12 metrics
P / E (TTM)
21.0
Trailing earnings · reciprocal yield 4.8%
PEG ratio
0.6
EV / revenue
2.0×
reciprocal yield 49.6%
EV / EBITDA
11.4×
reciprocal yield 8.8%
EV / EBIT
15.3×
reciprocal yield 6.5%
P / sales
2.4×
reciprocal yield 41.3%
P / book
4.0
reciprocal yield 24.7%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
13.6
reciprocal yield 7.3%
Earnings yield
4.8%

Historical valuation

8 metrics
P / E historical average (3Y)
12.3×
reciprocal yield 8.1%
P / E historical average (5Y)
13.2×
reciprocal yield 7.6%
EV / revenue historical average (3Y)
0.9×
reciprocal yield 114.0%
EV / revenue historical average (5Y)
0.8×
reciprocal yield 120.8%
EV / EBIT historical average (3Y)
6.6×
reciprocal yield 15.2%
EV / EBIT historical average (5Y)
11.9×
reciprocal yield 8.4%
EV / EBITDA historical average (3Y)
4.6×
reciprocal yield 21.7%
EV / EBITDA historical average (5Y)
5.1×
reciprocal yield 19.7%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-05
Last earnings
2026-10-22

Profitability

9 metrics
Gross margin
74.8%
Operating margin
13.2%
Trailing 12 months
Net margin
11.6%
Gross profit (TTM)
$173.04M
Operating profit (TTM)
$30.44M
Net income (TTM)
$26.72M
Trailing 12 months
Diluted EPS (TTM)
$0.52
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$4.49
Gross profit per diluted share (TTM)
$3.36
Operating profit per diluted share (TTM)
$0.59
EBITDA per diluted share (TTM)
$0.79
Net income per diluted share (TTM)
$0.52
Operating cash flow per diluted share (TTM)
$0.80
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$1.39
Stock compensation per diluted share (TTM)
$0.14
Book value per share
$2.59

Growth

11 metrics
Revenue growth YoY
+7.8%
Year over year
Net income growth YoY
+39.9%
Revenue (TTM)
$231.24M
Trailing 12 months
EPS growth YoY
+33.3%
Shares change YoY
+4.9%
Year over year · more shares
Revenue CAGR (3Y)
+0.0%
Revenue CAGR (5Y)
+0.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
+124.8%

Quality

14 metrics
Return on equity
19.3%
Return on assets
13.9%
Debt / equity
0.0
Current ratio
2.9
EBITDA (TTM)
$40.91M
Free cash flow (TTM)
—
Quick ratio
2.6
Interest coverage
8.6
Net debt / EBITDA
-2.3
Return on invested capital
—
Trailing 12 months
Net cash
$93.90M
Latest balance sheet
Cash & equivalents
$36.54M
Total assets
$192.74M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$41.15M
Capital expenditures (TTM)
$10,000
R&D (TTM)
$71.44M
SG&A (TTM)
$71.17M
Stock compensation (TTM)
$7.14M
R&D / revenue
30.9%
Stock compensation / revenue
3.1%

Ownership (13F)

9 metrics
13F filers
161
13F filer change QoQ
+3
Institutional ownership
75.1%
Conviction holders (share of 13F filers)
0.6%
Crowding (high-turnover and private-fund holders)
23.1%
Private-fund adviser ownership
22.3%
Active holders' share change QoQ
+0.9%
Holder tenure
13.4
Price vs estimated holder cost
+69.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
10.7%

Short interest

3 metrics
Short interest
8.8%
Latest settlement · 12.9 days to cover
Days to cover
12.9d
Short-squeeze score
77 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$612,494
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1401667 CUSIP 74587V107 13F (30d) 31 filings 31 filers Visit website Investor relations